Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 26156651

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2015 Aug
First author
Soria JC

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 Aug;16(8):872-3. doi: 10.1016/S1470-2045(15)00126-6.
    note
    Source null
    related pmid
    26156654
    relationship
    Comment in

Authors and identifiers

  1. name
    Soria JC
    type
    Author
  2. name
    Felip E
    type
    Author
  3. name
    Cobo M
    type
    Author
  4. name
    Lu S
    type
    Author
  5. name
    Syrigos K
    type
    Author
  6. name
    Lee KH
    type
    Author
  7. name
    Göker E
    type
    Author
  8. name
    Georgoulias V
    type
    Author
  9. name
    Li W
    type
    Author
  10. name
    Isla D
    type
    Author
  11. name
    Guclu SZ
    type
    Author
  12. name
    Morabito A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Soria JC
    type
    Author
  2. name
    Felip E
    type
    Author
  3. name
    Cobo M
    type
    Author
  4. name
    Lu S
    type
    Author
  5. name
    Syrigos K
    type
    Author
  6. name
    Lee KH
    type
    Author
  7. name
    Göker E
    type
    Author
  8. name
    Georgoulias V
    type
    Author
  9. name
    Li W
    type
    Author
  10. name
    Isla D
    type
    Author
  11. name
    Guclu SZ
    type
    Author
  12. name
    Morabito A
    type
    Author
bibliography ids
  1. nci-bib-32ee03f6b6de73db7b131964
book metadata
content sha256
e11e1d826b8558f85694032acb8527937e2210994ac7ea9ff6ee0b465b907856
document type
citation
dois
  1. 10.1016/S1470-2045(15)00006-6
electronic publication date
display
2015 Jul 5
precision
day
year
2015
evidence scope
bibliographic_metadata_only
id
pubmed:26156651
immutable id
pubmed:26156651@e11e1d826b8558f85694032acb8527937e2210994ac7ea9ff6ee0b465b907856
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
8
name
The Lancet. Oncology
nlm unique id
100957246
pages
897-907
volume
16
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 Aug;16(8):872-3. doi: 10.1016/S1470-2045(15)00126-6.
    note
    Source null
    related pmid
    26156654
    relationship
    Comment in
outcomes validated
false
pmid
26156651
provenance
batch id
4c1ece5bfc3d8e2be622
provider
NCBI PubMed ESummary
record sha256
a9d50ce9be00b66d801d88113065c1cb1631379a915c37a976d60b588427b037
response sha256
85f81bf7b60c457e4b5806b47c7c67c745ada2ae114069aa45de5ef977770dba
retrieved at
2026-09-09T23:47:12.730551+00:00
publication date
display
2015 Aug
precision
month
year
2015
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/26156651/
title
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

Preserved source evidence · Not medical advice